###begin article-title 0
###xml 15 25 15 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1/CIP1 </italic>
###xml 15 25 15 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1/CIP1 </italic></sup>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 156 166 156 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 226 230 226 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 226 236 226 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI</italic>
###xml 368 377 368 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI</italic></sup>
###xml 437 441 437 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 437 447 437 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 549 554 549 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 544 554 544 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 648 657 648 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
HER-2 (c-erbB2/Neu) predicts the prognosis of and may influence treatment responses in breast cancer. HER-2 activity induces the cytoplasmic location of p21WAFI/CIPI in cell culture, accompanied by resistance to apoptosis. p21WAFI/CIPI is a cyclin-dependent kinase inhibitor activated by p53 to produce cell cycle arrest in association with nuclear localisation of p21WAFI/CIPI. We previously showed that higher levels of cytoplasmic p21WAFI/CIPI in breast cancers predicted reduced survival at 5 years. The present study examined HER-2 and p21WAFI/CIPI expression in a series of breast cancers with up to 9 years of follow-up, to evaluate whether in vitro findings were related to clinical data and the effect on outcome.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 131 135 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 131 141 131 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
The CB11 anti-HER2 monoclonal antibody and the DAKO Envision Plus system were used to evaluate HER-2 expression in 73 patients. p21WAFI/CIPI staining was performed as described previously using the mouse monoclonal antibody Ab-1 (Calbiochem, Cambridge, MA, USA).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 107 109 107 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 152 154 152 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 254 264 254 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 375 377 375 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 442 446 442 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 447 452 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 442 452 442 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 474 476 474 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 539 542 539 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 544 547 544 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 539 549 539 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
HER-2 was evaluable in 67 patients and was expressed in 19% of cases, predicting reduced overall survival (P = 0.02) and reduced relapse-free survival (P = 0.004; Cox regression model). HER-2-positive tumours showed proportionately higher cytoplasmic p21WAFI/CIPI staining using an intensity distribution score (median, 95) compared with HER-2-negative cancers (median, 47) (P = 0.005). There was a much weaker association between nuclear p21WAFI/CIPI and HER-2 expression (P = 0.05), suggesting an inverse relationship between nuclear p21WAF1/CIP1 and HER-2.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 190 200 190 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI</italic>
###xml 261 270 261 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI</italic></sup>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 314 324 314 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIPI </italic></sup>
###xml 370 377 370 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
This study highlights a new pathway by which HER-2 may modify cancer behaviour. HER-2 as a predictor of poor prognosis may partly relate to its ability to influence the relocalisation of p21WAFI/CIPI from the nucleus to the cytoplasm, resulting in a loss of p21WAFI/CIPItumour suppressor functions. Cytoplasmic p21WAFI/CIPI may be a surrogate marker of functional HER-2 in vivo.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 500 502 500 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B </italic>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 700 701 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 865 866 865 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 220 225 <span type="species:ncbi:9606">human</span>
HER-2 is one of four Erb B family-type I receptor tyrosine kinases and is the preferred dimerisation partner for the epidermal growth factor receptor [1,2]. The Erb B receptors are important in normal development and in human cancer. HER-2, independent of its own ligand, activates other Erb B receptors to increase their ligand affinity and to amplify biological responses. HER-2 plays a key role in activating cytoplasmic signalling through the phosphatidylinositol-3 kinase (PI-3K)/protein kinase B (Akt) and mitogen-activated protein kinase pathways to influence transcription of nuclear genes [2-4]. Activation of PI-3K/Akt is involved in cell proliferation and confers resistance to apoptosis [5,6]. Breast cancer is associated with deregulated expression of HER-2, detectable as HER-2 amplification or protein overexpression identified in 10-40% of tumours [7]. HER-2 expression is indicative of poor prognosis and may predict tumour responses to hormone therapy and chemotherapy.
###end p 10
###begin p 11
###xml 107 110 107 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 112 115 112 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 107 116 107 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 353 356 353 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 358 361 358 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 353 363 353 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 441 444 441 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 446 449 446 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 441 451 441 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 723 726 723 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 728 731 728 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 723 733 723 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 777 780 777 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 782 785 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 777 787 777 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1001 1004 1001 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1006 1009 1006 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1001 1011 1001 1011 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 1130 1133 1130 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1135 1138 1135 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1130 1140 1130 1140 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1181 1189 1181 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo </italic>
###xml 1264 1267 1264 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1269 1272 1269 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1264 1274 1264 1274 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
Cell cycle progression is regulated by cyclin-dependent kinases (CDKs) associated with cyclin proteins. p21WAF1/CIP1, a downstream target of p53, is a CDK inhibitor that re-enforces p53-mediated G1 and G2 arrest following genotoxic insults, to facilitate DNA repair [8-11]. The integrity of G1 and G2 checkpoints requires the nuclear localisation of p21WAF1/CIP1 [11,12]. Recent evidence including subcellular fractionation suggests that p21WAF1/CIP1 can localise in the cytoplasm in cancer tissues and cell lines, where it inhibits apoptosis by binding and inhibiting the apoptosis signal-regulating kinase 1 [13-17]. Such an anti-apoptotic function in breast cancers could underlie the association between cytoplasmic p21WAF1/CIP1 and poor prognosis [17]. Upregulation of p21WAF1/CIP1 occurs through PI-3K/Akt signalling, and may involve insulin-like growth factors, p53-dependent pathways or HER-2 expression [18-20]. A HER-2-overexpressing breast cancer cell line transcriptionally upregulates p21WAF1/CIP1 and has been shown to produce its cytoplasmic localisation through a mechanism whereby Akt binds and phosphorylates p21WAF1/CIP1 in its nuclear localisation signal [21]. In vivo HER-2 expression may involve changes in the subcellular localisation of p21WAF1/CIP1 to influence the outcome in breast cancer.
###end p 11
###begin p 12
###xml 77 80 77 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 77 87 77 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 200 203 200 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 205 208 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 200 210 200 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 266 275 266 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 343 346 343 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 348 351 348 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 343 352 343 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 465 468 465 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 470 473 470 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 465 474 465 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 625 628 625 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 630 633 630 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 625 635 625 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 532 539 <span type="species:ncbi:9606">patient</span>
We previously found that breast cancers with higher levels of cytoplasmic p21WAF1/CIP1 predicted reduced overall survival (OS) and relapse-free survival (RFS), with correlation between cytoplasmic p21WAF1/CIP1 and p53 expression on immunohistochemistry [17]. Recent in vitro findings demonstrated a direct influence of HER-2 on cytoplasmic p21WAF1/CIP1. This influence prompted us to investigate HER-2 expression in a retrospective series of breast cancers with p21WAF1/CIP1staining by immunohistochemistry and a further 4 years of patient follow-up [21]. We are not aware of any other study to date examining subcellular p21WAF1/CIP1 expression in relation to HER-2 immunoreactivity.
###end p 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 14
###begin p 15
###xml 22 30 <span type="species:ncbi:9606">patients</span>
The study included 73 patients aged 32-80 years (median, 55 years) with primary infiltrating carcinoma diagnosed between 1989 and 1992 at the John Radcliffe Hospital. The eligibility criteria were histological diagnosis of breast carcinoma, level one or complete axillary lymph node dissection, no distant metastases and unilateral tumour. Forty-nine (67%) cases were node-negative and 24 (33%) cases were node-positive (N1-mobile ipsilateral or N2-fixed ipsilateral).
###end p 15
###begin p 16
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Clinicopathological subgroups were analysed according to the Nottingham Prognostic Index (NPI). They were divided into good, moderate and poor prognostic groups as previously described, with a modification that included no assessment of the internal mammary lymph nodes [22,23]. Seventeen nongraded nonductal cancers were not included in the NPI groups.
###end p 16
###begin p 17
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 359 364 <span type="species:ncbi:9606">women</span>
Adjuvant treatment groups comprised tamoxifen (16 node-negative patients, 14 node-positive patients), cyclophosphamide/methotrexate/5-fluorouracil (six node-negative patients, six node-positive patients), and both tamoxifen plus cyclophosphamide/methotrexate/5-fluorouracil (two node-negative patients, four node-positive patients). Twenty-five node-negative women received no adjuvant treatment.
###end p 17
###begin p 18
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
The median duration of follow-up was 110 months (range, 46-144 months) among patients who were alive at the date of their last visit. Tumour samples were collected shortly after surgery and were fixed in buffered formalin for 24-48 hours at room temperature. Tumours were classified according to Azzopardi [24]. Invasive ductal carcinomas were graded by the modified Bloom's grading system described by Elston and Ellis [25]. The oestrogen receptor (ER) status was determined using an ELISA assay (Abbott-ERICA; Abbott Laboratories, Maidenhead, UK). Tumours were classified as ER-positive if oestradiol binding exceeded 10 fmol/mg cytosolic protein.
###end p 18
###begin title 19
Immunohistochemistry
###end title 19
###begin p 20
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
###xml 404 408 <span type="species:ncbi:9925">goat</span>
###xml 441 452 <span type="species:ncbi:3704">horseradish</span>
HER-2 immunostaining was performed using the mouse monoclonal anti-HER-2 antibody (RTU-CB11) (NovaCastra/ Vector, Newcastle upon Tyne, UK), and the DAKO Envision Plus HRP system (K4006; DAKO, Ely, Cambridgeshire, UK). Formalin-fixed paraffin sections of breast cancer tissue were baked, dewaxed and rehydrated prior to a peroxidase block (0.1%, v/v hydrogen peroxide) and an incubation in 10% v/v normal goat serum. The primary antibody and horseradish peroxide-labelled polymer were used as per the DAKO Envision kit, followed by 3,3-diaminobenzidine and counterstaining with haematoxylin before mounting.
###end p 20
###begin p 21
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
HER-2 expression was scored according to the degree and the proportion of membrane staining [26]. HER-2 expression was negative for a score of 0 or 1+. A score of 0 was defined as no staining or membrane staining in less than 10% of tumour cells. A score of 1+ comprised faint or partly-stained membranes in more than 10% of tumour tissue. Overexpression of c-erbB2 was scored as 2+, defined as weak to moderate complete membrane staining in more than 10% of tumour cells. A score of 3+ was interpreted as strong, complete membrane staining in more than 10% of tumour. This was analysed in the Department of Clinical Laboratory Sciences (by RDL).
###end p 21
###begin p 22
###xml 3 6 3 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 3 13 3 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 290 293 288 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 295 299 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP </italic>
###xml 290 299 288 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP </italic></sup>
###xml 310 312 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 464 467 462 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 469 472 467 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 464 473 462 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 575 578 573 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 580 583 578 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 575 585 573 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 730 732 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 996 998 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
###xml 146 150 <span type="species:ncbi:9925">goat</span>
###xml 156 161 <span type="species:ncbi:10090">mouse</span>
p21WAF1/CIP1 immunoreactivity was evaluated using the mouse monoclonal antibody Ab-1 (Calbiochem, Cambridge, MA, USA) at 0.5 mug/ml. Biotinylated goat anti-mouse IgG (DAKO, Glostrup, Denmark) secondary antibody was used at 15 mug/ml. The Strept ABC Duet kit (DAKO, Denmark) was used for p21WAF1/CIP detection [17]. Immunostaining was assessed using a Laborlux microscope (Leitz, Wetzlar, Germany) at 400x overall magnification with a field diameter of 0.46 mm. p21WAF1/CIP1immunoreactivity was assessed as the degree of staining intensity and the proportion of cells with p21WAF1/CIP1 in the nucleus and in the cytoplasm, which was graded semiquantitatively to produce an intensity distribution score (IDS) for each localisation [17]. Calculation of the IDS was performed as follows: IDS (maximum score 300) = 1 x per cent of weakly stained cells + 2 x per cent of moderately stained cells + 3 x per cent of strongly stained cells. Average IDS values were determined by examination of 10 fields [17].
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 248 251 248 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 243 253 243 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 308 311 308 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 308 318 308 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 34 41 <span type="species:ncbi:9606">patient</span>
The association between HER-2 and patient characteristics was assessed using the Mann-Witney test for continuous variables and the chi-squared test for categorical factors. The relationship between HER-2 and the subcellular localisation of p21WAF1/CIP1 was analysed using the Mann-Witney U test, with the p21WAF1/CIP1 IDS used as a continuous variable. Analyses of survival data were performed using the log-rank test and the Cox regression model, with survival curves computed using the Kaplain-Meier method.
###end p 24
###begin p 25
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 27 30 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 22 32 22 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 526 533 <span type="species:ncbi:9606">patient</span>
###xml 569 577 <span type="species:ncbi:9606">patients</span>
For both HER-2 and p21WAF1/CIP1 markers univariate and multivariate analyses were performed, the latter adjusting for the NPI score and the treatment received (tamoxifen/ chemotherapy/no treatment). As the NPI is based on nodal involvement, on tumour size and on grade, patients with histologies for whom grade is undefined ('other' cancers) were excluded from the regression analyses. Thirteen patients (all either ductal carcinoma, lobular carcinoma or mixed histology) had no grade information recorded in the data and one patient had no tumour size recorded. These patients were included in the analysis using multiple imputation methods [27] to estimate the missing values.
###end p 25
###begin p 26
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
The hazard ratios were derived from the average effect across 10 augmented datasets, with the confidence intervals and significance tests taking into account the uncertainty of the imputations. The multiple imputation was performed by the MICE library within the S-Plus 2000 Guide to Statistics Volumes 1 and 2 (MathSoft, Seattle, WA, USA), and all other analyses were performed using the STATA version 7 software (STATA Corporation, College Station, TX, USA) [28].
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
HER-2 expression and association with clinicopathologic factors
###end title 28
###begin p 29
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 408 410 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 465 467 461 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
HER-2 immunoreactivity was evaluable in 67 (92%) cases, and scored positively in 13 (19%) cases (Fig. 1) using scoring of 2+ and 3+ as indicative of HER-2 protein overexpression. Tumours with HER-2 scores of 0 or 1+ were assessed as negative. HER-2 expression was analysed in relation to clinicopathologic criteria (Table 1), with a significant association of HER-2 positivity with young age (</= 50 years) (P = 0.03) and with ER-negative (</= 10 fmol/mg) tumours (P = 0.05).
###end p 29
###begin title 30
###xml 57 66 57 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1/CIP1</italic>
###xml 57 66 57 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1/CIP1</italic></sup>
Association of HER-2 with subcellular localisation of p21WAF1/CIP1
###end title 30
###begin p 31
###xml 3 6 3 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 3 13 3 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAFI</italic>
###xml 150 153 150 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 145 155 145 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAFI</italic>/<italic>CIP</italic>1 </sup>
###xml 318 320 318 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 353 356 353 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 358 361 358 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 353 363 353 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 467 469 467 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
p21WAF1/CIP1 expression measured as an IDS was analysed in the nucleus and in the cytoplasm in relation to HER-2 expression (Fig. 1). Nuclear p21WAFI/CIP1 was higher in HER-2-negative tumours with a median IDS of 7.3 (range, 0-88.5), compared with a median IDS of 2.3 (range, 0-37.5) in HER-2-positive breast cancers (P = 0.05) (Fig. 2). Cytoplasmic p21WAF1/CIP1 staining was significantly higher in HER-2-positive cancers with a median IDS of 95 (range, 12.5-154.5; P = 0.005), compared with HER-2-negative tumours with a median IDS of 47 (range, 0-134.6) (Fig. 2).
###end p 31
###begin p 32
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 92 95 92 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 87 97 87 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 169 172 169 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 174 177 174 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 169 178 169 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 221 224 221 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 226 229 226 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 221 231 221 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 391 394 391 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 396 399 396 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 391 401 391 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 454 457 454 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 459 462 459 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 454 463 454 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
These results suggest that HER-2-positive tumours showed an increase in cytoplasmic p21WAF1/CIP1 of 50 IDS units, compared with a decrease of 5 IDS units for nuclear p21WAF1/CIP1. Despite proportionately lower nuclear p21WAF1/CIP1 levels on IDS, the HER-2-associated increase is far greater in terms of cytoplasmic immunoreactivity. This suggests that the association between cytoplasmic p21WAF1/CIP1 and HER-2 positivity is stronger than for nuclear p21WAF1/CIP1.
###end p 32
###begin title 33
###xml 102 112 102 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1/CIP1 </italic>
###xml 102 112 102 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1/CIP1 </italic></sup>
Relationship of clinicopathological factors to prognosis and the predictive potential of HER-2 and p21WAF1/CIP1 expression
###end title 33
###begin p 34
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 128 133 <span type="species:ncbi:9606">women</span>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
At 9 years, disease relapses were seen in 33 patients (22 of 48 node-negative patients and 11 of 25 node-positive patients); 30 women died from breast carcinoma. The 9-year RFS and OS were 52% and 61%, respectively. Poor prognostic factors such as the presence of lymph node metastases, high tumour grade, large tumour size and negative ER status were all associated with a lower percentage of patients remaining disease-free (RFS) and alive (OS) at 9 years (data not shown). The 5-year OS of the NPI subgroups were 67% (95% confidence interval, 19-95%) for the good prognostic group, 78% (95% confidence interval, 61-88%) for the moderate prognostic group and 40% (95% confidence interval, 12-67%) for the poor prognostic group, respectively.
###end p 34
###begin p 35
###xml 176 179 176 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 181 184 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 176 186 176 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 285 287 285 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 316 318 316 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 363 366 363 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP </italic>
###xml 363 372 363 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP </italic></sup>
###xml 451 453 451 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 681 684 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP </italic>
###xml 681 690 681 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP </italic></sup>
###xml 744 747 744 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 749 753 749 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP </italic>
###xml 744 753 744 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP </italic></sup>
###xml 93 100 <span type="species:ncbi:9606">patient</span>
Univariate and multivariate analyses were used to investigate possible relationships between patient survival data and HER-2 expression, and the subcellular distribution of p21WAF1/CIP1 (Table 2). Univariate analysis showed that HER-2 was significantly associated with a decreased OS (P = 0.05) and a decreased RFS (P = 0.02) (Table 2 and Fig. 3). Cytoplasmic p21WAF1/CIP was associated with a decreased OS and a decreased RFS on univariate analysis (P = 0.03) (Table 2). The multivariate analysis was adjusted for the NPI and treatment groups (no treatment, tamoxifen, other) (Table 2). Multivariate analysis demonstrated the independent prognostic significance of cytoplasmic p21WAF1/CIP and HER-2 in relation to OS and RFS, while nuclear p21WAF1/CIP was not a prognosticator in this study.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 51 60 51 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 183 191 183 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 583 591 583 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 307 314 <span type="species:ncbi:9606">patient</span>
HER-2 enhances cancer cell growth, and a number of in vitro studies have highlighted mechanisms to explain its oncogenic potential [18,19,21,29-31]. The relevance of these mechanisms in vivo requires further investigation. Analysis of HER-2 expression in breast cancer is important in the interpretation of patient prognosis and treatment response. In this study, the immunohistochemical detection of HER-2 was in keeping with the reported frequency of protein expression in breast cancers. Despite controversy surrounding the relative value of immunohistochemistry and fluorescence in situ hybridisation to evaluate HER-2 overexpression, a recent study has shown good concordance for both tests [32].
###end p 37
###begin p 38
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 262 271 262 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 316 321 316 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
HER-2 positivity independently predicted prognosis in this group of breast cancers, and was associated with lack of ER expression (Tables 1 and 2, and Fig. 3). Mechanisms underpinning the association of HER-2 with ER-negative tumours need to be determined, with in vitro evidence indicating a negative regulation of HER2 transcription by steroid hormones [29]. Clinical relevance of these pathways may underlie hormone resistance in HER-2-expressing breast cancers [30].
###end p 38
###begin p 39
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 213 222 213 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 239 242 239 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 244 247 244 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 239 249 239 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 310 313 310 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 315 318 315 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 310 320 310 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 485 488 485 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 490 494 490 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP </italic>
###xml 485 494 485 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP </italic></sup>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 593 596 593 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 598 601 598 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 593 603 593 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
HER-2 potentiates ligand-induced intracellular signalling by targeting the Akt oncoprotein that mediates cytoplasmic PI-3K signalling [21]. Through this mechanism, HER-2 and Akt have been shown to block apoptosis in vitro by regulating p21WAF1/CIP1 and by enhancing p53 degradation [21,31]. HER-2 increases p21WAF1/CIP1 expression to inhibit the mitotic CDC2 kinase and to block Taxol-induced apoptosis [19]. Through an alternative anti-apoptotic pathway, HER-2 induces cytoplasmic p21WAF1/CIP [21]. Immunofluorescence and subcellular fractionation have previously demonstrated cytoplasmic p21WAF1/CIP1 in cell lines characterised by transformation, anchorage independence and anti-apoptosis [13-16].
###end p 39
###begin p 40
###xml 27 30 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 27 37 27 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 219 222 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 224 227 224 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 219 229 219 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 267 270 267 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 272 275 272 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 267 277 267 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 626 629 626 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 631 634 631 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 626 636 626 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 652 661 652 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 676 677 676 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 682 683 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 762 765 762 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 767 770 767 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 762 772 762 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 827 830 827 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 832 835 832 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 827 836 827 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 849 852 849 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 854 857 854 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 849 859 849 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 1110 1113 1110 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1115 1118 1115 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1110 1120 1110 1120 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 1145 1153 1145 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 1190 1193 1190 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1195 1198 1195 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1190 1200 1190 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 1294 1297 1294 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1299 1302 1299 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1294 1303 1294 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 1304 1306 1304 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1432 1435 1432 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1437 1440 1437 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1432 1442 1432 1442 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 1530 1532 1530 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1623 1626 1623 1626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1628 1631 1628 1631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1623 1633 1623 1633 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 1650 1659 1650 1659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1663 1670 1663 1670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1731 1734 1731 1734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1736 1739 1736 1739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1731 1740 1731 1740 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
Predominant cytoplasmic p21WAF1/CIP1 has been detected immunohistochemically in breast tumours and in ovarian tumours [15,17]. Previous studies of breast carcinoma have reported the exclusive nuclear localisation of p21WAF1/CIP1 [33-35]. In our study, cytoplasmic p21WAF1/CIP1 staining was evident as previously reported [33,36,37] and was based on the method of microwave antigen retrieval (Fig. 1b) using an alkaline buffer (Tris-buffered saline/EDTA, pH 9.0), rather than the acidic citrate buffer (pH 6.0) [17,34,35]. This series of breast cancers shows an important association between HER-2 and increased cytoplasmic p21WAF1/CIP1 to substantiate in vitro findings (Figs 1 and 2) [21]. An inverse association between the HER-2 breast tumours and nuclear p21WAF1/CIP1 further implies the ability of HER-2 to mislocalise p21WAF1/CIP1. Nuclear p21WAF1/CIP1 is required to preferentially inhibit cyclin/CDK complexes to ensure DNA repair and growth suppression of transformed cells. This process is determined by a carboxyterminal nuclear localisation signal, while mechanisms underlying nuclear export of p21WAF1/CIP1 remain to be determined. In vitro, active phosphorylated Akt binds p21WAF1/CIP1 and phosphorylates threonine 145 in the nuclear localisation signal to produce cytoplasmic p21WAF1/CIP1[21]. In a preliminary series of five breast cancers, immunohistochemical detection of phosphorylated Akt was associated with p21WAF1/CIP1 in both the nucleus and the cytoplasm, suggesting an association with HER-2 activation [21]. This implies that the relationship between HER-2 and the subcellular localisation of p21WAF1/CIP1 is not exclusive in vitro and in vivo, but reflects a preferential cytoplasmic localisation of p21WAF1/CIP1.
###end p 40
###begin p 41
###xml 8 16 8 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 145 148 145 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 150 153 150 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 145 154 145 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 224 227 224 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 224 234 224 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 339 342 339 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 339 349 339 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 468 471 468 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 473 476 473 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 468 477 468 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 590 593 590 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 595 598 595 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 590 600 590 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 770 773 770 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 775 778 775 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 770 780 770 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 692 699 <span type="species:ncbi:9606">patient</span>
Further in vivo studies are required to establish the significance of phosphorylated Akt in relation to HER-2 and subcellular localisation of p21WAF1/CIP1, with future possibilities that immunodetection of phosphorylated p21WAF1/CIP1 may imply activation of this pathway. Clinical relevance of HER-2-expressing tumours with cytoplasmic p21WAF1/CIP1 is emphasised by the independent prognostic significance of both parameters. Prognostic significance of cytoplasmic p21WAF1/CIP1at 5 years retains its predictive potential for OS and RFS at 9 years. The combined evaluation of cytoplasmic p21WAF1/CIP1 and HER-2 positively did not increase prognostic significance in this study, due to limited patient numbers in the respective subsets. As previously reported, nuclear p21WAF1/CIP1 expression was generally low and provided no prognostic information [17,33,35]. Future studies will be required to address what are the best markers.
###end p 41
###begin p 42
###xml 46 49 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 46 56 46 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 348 351 348 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 353 356 353 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 348 358 348 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 463 466 463 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 468 471 468 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 463 472 463 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 648 651 648 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 653 656 653 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 648 657 648 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 872 875 872 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 877 880 877 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 872 882 872 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 927 930 927 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 932 935 932 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 927 936 927 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 1108 1111 1108 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 1113 1116 1113 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 1108 1117 1108 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 562 569 <span type="species:ncbi:9606">patient</span>
The biological implications of cytoplasmic p21WAF1/CIP1 with respect to the ability to assemble and inhibit cyclin/CDK complexes and to bind apoptosis signal-regulating kinase 1 require further investigation. Studies in cell culture suggest a loss of p53 and growth suppressor function, with inhibition of apoptosis. Subcellular localisation of p21WAF1/CIP1 may have relevance underlying mechanisms of HER-2 drug resistance, with the potential for cytoplasmic p21WAF1/CIP1-expressing breast tumours to have increased chemoresistance or hormone resistance. Small patient numbers precluded a separate analysis of treatment relapses in cytoplasmic p21WAF1/CIP1-expressing tumours. The potential to define and modify this pathway through Herceptin inhibition of HER-2 or through Iressa inhibition of HER-1 could influence downstream targets of the pathways such as Akt and p21WAF1/CIP1 [38]. The ability of HER-2 to dysregulate p21WAF1/CIP1, a key target of p53, is highly relevant in the context of p53 wild-type cancers, in which growth suppression and apoptosis may be inhibited through mislocalisation of p21WAF1/CIP1.
###end p 42
###begin title 43
Conclusion
###end title 43
###begin p 44
###xml 151 154 151 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 151 161 151 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 275 278 275 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 270 280 270 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 452 455 452 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 457 460 457 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 452 462 452 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 521 529 521 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 675 678 675 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 680 683 680 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 675 685 675 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 747 750 747 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 752 755 752 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 747 757 747 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1011 1013 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
These presented findings indicate that HER-2 expression may influence tumour outcome through a mechanism regulating the subcellular localisation of p21WAF1/CIP1 to produce a cytoplasmic distribution resulting in a loss of its tumour suppressor functions. Cytoplasmic p21WAF1/CIP1 predicts poor prognostic tumours and may have a role in HER-2-mediated drug resistance, with the potential for future therapeutic manipulation by Herceptin. Cytoplasmic p21WAF1/CIP1 may conceivably be a surrogate marker for HER-2 signalling in vivo to classify clinical subgroups of patients most likely to benefit from Herceptin, such that Herceptin inhibition of the pathway could relocate p21WAF1/CIP1 to the nucleus. A cytoplasmic to nuclear relocalisation of p21WAF1/CIP1 could be a useful biological endpoint to analyse the potential efficacy of Herceptin. Other growth factor pathways involving insulin have recently been implicated in Herceptin resistance, suggesting biological modifications of the Herceptin response [20,39]. Increasingly, there is a rationale for identifying biological markers of drug responsiveness.
###end p 44
###begin title 45
Competing interests
###end title 45
###begin p 46
None declared.
###end p 46
###begin title 47
Abbreviations
###end title 47
###begin p 48
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
Akt = protein kinase B; CDK = cyclin-dependent kinases; ELISA = enzyme-linked immunosorbent assay; ER = oestrogen receptor; IDS = intensity distribution score; NPI = Nottingham Prognostic Index; OS = overall survival; PI-3K = phosphatidylinositol-3 kinase; RFS = relapse-free survival.
###end p 48
###begin title 49
Acknowledgements
###end title 49
###begin p 50
###xml 18 22 <span type="species:ncbi:4681">Leek</span>
ZE Winters and RD Leek contributed equally to this work. This work was supported by Cancer Research UK and the Nuffield Foundation (Fellowship to ZEW).
###end p 50
###begin article-title 51
The ErbB receptor tyrosine family as signal integrators
###end article-title 51
###begin article-title 52
Role of HER2 gene overexpression in breast carcinoma
###end article-title 52
###begin article-title 53
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation
###end article-title 53
###begin article-title 54
PDGF-and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase
###end article-title 54
###begin article-title 55
Mechanisms and consequences of activation of protein kinase B/Akt
###end article-title 55
###begin article-title 56
Cellular survival: a play in three Akts
###end article-title 56
###begin article-title 57
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
###end article-title 57
###begin article-title 58
Participation of p53 protein in the cellular response to DNA damage
###end article-title 58
###begin article-title 59
Radiation-induced cell cycle arrest compromised by p21 deficiency
###end article-title 59
###begin article-title 60
###xml 51 56 <span type="species:ncbi:9606">human</span>
p21 is necessary for the p53-mediated G1 arrest in human cancer cells
###end article-title 60
###begin article-title 61
###xml 107 112 <span type="species:ncbi:9606">human</span>
p53 regulates Cdc2 independently of inhibitory phosphorylation of reinforce radiation-induced G2 arrest in human cells
###end article-title 61
###begin article-title 62
###xml 27 30 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cip</italic>
###xml 27 32 27 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Cip</italic>1 </sup>
Nuclear accumulation of p21Cip1 at the onset of mitosis: a role of the G2/M-phase transition
###end article-title 62
###begin article-title 63
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cip</italic>
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Waf</italic>
###xml 33 43 33 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Cip</italic>1/<italic>Waf</italic>1 </sup>
Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells
###end article-title 63
###begin article-title 64
###xml 56 61 56 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Cip1 </sup>
###xml 68 73 68 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Kip1 </sup>
Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells
###end article-title 64
###begin article-title 65
###xml 26 31 <span type="species:ncbi:9606">human</span>
Increased level of p21 in human ovarian tumors is associated with increased expression of CDK2, cyclin A and PCNA
###end article-title 65
###begin article-title 66
###xml 48 58 48 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Cip1/WAF1 </sup>
Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation
###end article-title 66
###begin article-title 67
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1</italic>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIPI </italic>
###xml 50 60 50 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1</italic>/<italic>CIPI </italic></sup>
Subcellular localization of cyclin B, Cdc2 and p21WAF1/CIPI in breast cancer: association with prognosis
###end article-title 67
###begin article-title 68
###xml 112 127 112 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WAF1/CIP1/SDI1 </sup>
The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel
###end article-title 68
###begin article-title 69
###xml 77 81 77 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Cip1</sup>
###xml 101 106 101 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Cdc2 </sup>
Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase
###end article-title 69
###begin article-title 70
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF </italic>
###xml 41 49 41 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CIP</italic>/<italic>WAF </italic></sup>
###xml 118 123 <span type="species:ncbi:9606">human</span>
The cyclin dependent kinase inhibitor p21CIP/WAF is a positive regulator of IGF-1-induced cell proliferation in MCF-7 human breast cancer cells
###end article-title 70
###begin article-title 71
###xml 31 41 31 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Cip1/WAF1 </sup>
Cytoplasmic localisation of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells
###end article-title 71
###begin article-title 72
The Nottingham prognostic index in primary breast cancer
###end article-title 72
###begin article-title 73
The prognosis of small primary breast cancers
###end article-title 73
###begin article-title 74
Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer: experience from a large study with long-term follow-up
###end article-title 74
###begin article-title 75
Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries
###end article-title 75
###begin article-title 76
Multiple imputation of missing blood pressure covariates in survival analysis
###end article-title 76
###begin article-title 77
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer
###end article-title 77
###begin article-title 78
Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer
###end article-title 78
###begin article-title 79
HER-2/ neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
###end article-title 79
###begin article-title 80
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
###end article-title 80
###begin article-title 81
###xml 3 8 3 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1 </italic>
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1 </italic></sup>
p21WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment
###end article-title 81
###begin article-title 82
###xml 32 37 <span type="species:ncbi:9606">human</span>
WAF1/CIP1 protein expression in human breast tumours
###end article-title 82
###begin article-title 83
p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis
###end article-title 83
###begin article-title 84
p21waf correlates with DNA replication but not with prognosis in invasive breast cancer
###end article-title 84
###begin article-title 85
p21 (WAF1) expression and endocrine response in breast cancer
###end article-title 85
###begin article-title 86
###xml 5 10 <span type="species:ncbi:9606">human</span>
Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer
###end article-title 86
###begin article-title 87
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin)
###end article-title 87
###begin title 88
Figures and Tables
###end title 88
###begin p 89
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 25 35 25 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 218 222 218 222 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 266 270 266 270 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 315 318 315 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 320 323 320 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 315 324 315 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
###xml 362 365 362 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 367 370 367 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 362 372 362 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 384 388 384 388 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 418 422 418 422 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 451 454 451 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 456 459 456 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 451 461 451 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 506 509 506 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 501 510 501 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1</sup>
Examples of HER-2 and p21WAF1/CIP1 immunoreactivity in infiltrating ductal carcinoma of the breast. Immunostaining was performed as described in Materials and methods, and nuclei were counterstained with haematoxylin. (a) A tumour showing HER-2 overexpression, with (b) a concomitant predominance of cytoplasmic p21WAF1/CIP1staining and minimal or no nuclear p21WAF1/CIP1 expression. (c) A HER-2-negative tumour, with (d) a predominance of nuclear p21WAF1/CIP1 expression compared with cytoplasmic p21WAF1/CIP1, which was proportionately less on intensity distribution scoring in 10 fields. Insets in panels (b) and (d) show higher-power views of the same fields. Magnification x 3-4.
###end p 89
###begin p 90
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 39 42 39 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 34 44 34 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 137 140 137 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 142 145 142 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 137 147 137 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 265 268 265 268 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 295 298 295 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 300 303 300 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 295 305 295 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 412 416 412 416 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 431 434 431 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 436 439 436 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 431 441 431 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 540 543 540 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 545 548 545 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 540 550 540 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 620 622 620 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 389 396 <span type="species:ncbi:9606">patient</span>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
###xml 519 527 <span type="species:ncbi:9606">patients</span>
###xml 576 584 <span type="species:ncbi:9606">patients</span>
Relationship between HER-2 and p21WAF1/CIP1 localisation. Scatter plots according to HER-2 status and the subcellular localisation of p21WAF1/CIP1 measured as an intensity distribution score (IDS). HER-2 staining was analysed as described in Materials and methods. (a)Distribution of nuclear p21WAF1/CIP1 IDS and medians according to HER-2-negative and HER-2-positive breast cancers, with patient numbers shown. (b) Cytoplasmic p21WAF1/CIP1 IDS and medians according to HER-2 status, and numbers of patients. Of the 67 patients, nuclear p21WAF1/CIP1 was not evaluable in four patients, or in the cytoplasm in six cases. P values indicate significance.
###end p 90
###begin p 91
###xml 81 85 81 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 207 211 207 211 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 283 285 283 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Relationship between HER-2 and prognosis in 67 patients using the log-rank test. (a) Overall survival curves according to HER-2 status, classified as negative or positive according to Materials and methods. (b) Relapse-free survival curves according to HER-2 expression. Significant P values are indicated in bold.
###end p 91
###begin p 92
Clinicopathological variables according to c-erbB2 status
###end p 92
###begin p 93
###xml 124 126 124 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
GPG, good prognostic group; MPG, moderate prognostic group; PPG, poor prognostic group. *Relationship reached significance (P </= 0.05).
###end p 93
###begin p 94
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 35 45 35 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 45 100 45 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">localisation and overall survival/relapse-free survival</bold>
Relationships between HER-2 and p21WAF1/CIP1 localisation and overall survival/relapse-free survival
###end p 94
###begin p 95
###xml 40 42 40 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 238 241 238 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF</italic>
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CIP</italic>
###xml 238 248 238 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>
###xml 857 859 857 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 429 437 <span type="species:ncbi:9606">Patients</span>
Hazard ratios, confidence intervals and P values are given for the results of both the univariate analyses and the multivariate analyses. For univariate and multivariate analyses, the hazard ratio is given for nuclear and cytoplasmic p21 WAF1/CIP1 per 10 unit increase in intensity distribution score (IDS), along with the 95% confidence interval. The hazard ratio and confidence interval for HER-2 relates to 2+/3+ versus 0/1+. Patients with ductal, lobular or 'mixed' cancer were included where the marker data was available. The multivariate analysis is adjusted for the Nottingham Prognostic Index (NPI) (nodes, grade and size) and for treatment (tamoxifen/chemotherapy/no treatment), with the NPI based on imputed grades and tumour sizes where the relevant data were missing as described in the statistical methods. *Relationship reached significance (P < 0.05).
###end p 95

